NOS2 and cancer: Overall, the evaluation of the expression level of NOS isoforms in cancer cells and in specific inflammatory/immune cell subtypes present in the tumor microenvironment in relation to tumor aggressiveness and EMT/EndMT needs to be further assessed both for diagnostic use and personalized treatment choice and to adequately design the immunotherapy/target therapy/chemotherapy combination.